Orangetheory Fitness: Nasm Training for Glp-1 Era - Nov 16

Share this article
Spread the word on social media
The Story
Orangetheory Fitness says it is training all coaches through the National Academy of Sports Medicine (NASM) on how to support clients using GLP-1 medications. The initiative positions the privately held brand to address exercise and muscle-preserving strength work alongside weight-loss treatment, but no financial targets were disclosed.
Why It Matters For Your Portfolio
- Orangetheory calls itself the first fitness brand to partner with NASM to train all coaches for the GLP-1 era. That may help distinguish its member offering, though the announcement doesn’t quantify expected enrollment or retention.
- The program addresses clients using drugs such as semaglutide and tirzepatide, reflecting growing demand for weight-management support. No figures on that demand or Orangetheory’s potential share were provided.
- Orangetheory is privately held and has no stock ticker, so this is not a direct public-market catalyst for an OTF stock. Its parent, Purpose Brands, formed in 2024 through a merger involving Orangetheory’s parent.
- The announcement gives no training costs, member uptake, retention effects, or revenue expectations. Coach education also doesn’t establish clinical validation or suitability for every person using GLP-1 medication.
The Trade
Growth investors tracking the fitness and weight-management industries can watch for evidence that the training leads to new programming, partnerships, or stronger member retention. For public-market analysis, there’s no disclosed stock price or company valuation data here, and no OTF ticker to trade.
Before drawing conclusions about commercial value, look for reported uptake, costs, and financial results. Clients using GLP-1 medications may need individualized medical guidance; the training announcement doesn’t replace it.